188 related articles for article (PubMed ID: 29311482)
1. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
[TBL] [Abstract][Full Text] [Related]
3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
4. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
Arbitrio M; Di Martino MT; Barbieri V; Agapito G; Guzzi PH; Botta C; Iuliano E; Scionti F; Altomare E; Codispoti S; Conforti S; Cannataro M; Tassone P; Tagliaferri P
Cancer Chemother Pharmacol; 2016 Jan; 77(1):205-9. PubMed ID: 26607259
[TBL] [Abstract][Full Text] [Related]
5. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
6. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Thomas F; Rochaix P; White-Koning M; Hennebelle I; Sarini J; Benlyazid A; Malard L; Lefebvre JL; Chatelut E; Delord JP
Eur J Cancer; 2009 Sep; 45(13):2316-23. PubMed ID: 19523815
[TBL] [Abstract][Full Text] [Related]
10. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Hamada A; Sasaki J; Saeki S; Iwamoto N; Inaba M; Ushijima S; Urata M; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Kai Y; Isobe T; Kohrogi H; Saito H
Pharmacogenomics; 2012 Apr; 13(5):615-24. PubMed ID: 22462752
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Ma Y; Xin S; Huang M; Yang Y; Zhu C; Zhao H; Zhang Y; Chen L; Zhao Y; Li J; Zhuang W; Zhu X; Zhang L; Wang X
Pharmacogenomics J; 2017 Jul; 17(4):325-330. PubMed ID: 27089937
[TBL] [Abstract][Full Text] [Related]
13. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
[TBL] [Abstract][Full Text] [Related]
16. Genetic Variants in the
Morau MV; Seguin CS; Visacri MB; Pincinato EC; Moriel P
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790220
[TBL] [Abstract][Full Text] [Related]
17. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
